Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies.
Santoni M, Molina-Cerrillo J, Myint ZW, Massari F, Buchler T, Buti S, Matrana MR, De Giorgi U, Rizzo M, Zabalza IO, Galli L, Zucali PA, Aurilio G, Incorvaia L, Bassanelli M, Mammone G, Salfi A, Isella L, Mollica V, Grande E, Porta C, Battelli N. Santoni M, et al. Among authors: matrana mr. Target Oncol. 2022 Sep;17(5):571-581. doi: 10.1007/s11523-022-00907-9. Epub 2022 Aug 10. Target Oncol. 2022. PMID: 35947324
BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
Piva F, Santoni M, Matrana MR, Satti S, Giulietti M, Occhipinti G, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M, Principato G, Cascinu S, Montironi R. Piva F, et al. Among authors: matrana mr. Expert Rev Mol Diagn. 2015;15(9):1201-10. doi: 10.1586/14737159.2015.1068122. Epub 2015 Jul 11. Expert Rev Mol Diagn. 2015. PMID: 26166446 Review.
Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
Matrana MR, Bathala T, Campbell MT, Duran C, Shetty A, Teegavarapu P, Kalra S, Xiao L, Atkinson B, Corn P, Jonasch E, Tannir NM. Matrana MR, et al. BJU Int. 2016 Aug;118(2):264-71. doi: 10.1111/bju.13374. Epub 2015 Dec 13. BJU Int. 2016. PMID: 26573089 Free PMC article.
Emerging Immunotargets in Metastatic Renal Cell Carcinoma.
Kucharczyk J, Matrana MR, Santoni M, Massari F, Scarpelli M, Cheng L, Lopez-Beltran A, Cascinu S, Montironi R, Holger M. Kucharczyk J, et al. Among authors: matrana mr. Curr Drug Targets. 2016;17(7):771-6. doi: 10.2174/1389450117666151209115753. Curr Drug Targets. 2016. PMID: 26648075 Review.
An Overview of Emerging Immunotargets of Genitourinary Tumors.
Montironi R, Santoni M, Cheng L, Lopez-Beltran A, Massari F, Matrana MR, Moch H, Scarpelli M. Montironi R, et al. Among authors: matrana mr. Curr Drug Targets. 2016;17(7):750-6. doi: 10.2174/1389450117666151209144649. Curr Drug Targets. 2016. PMID: 26648079 Review.
Emerging Immunotargets in Bladder Cancer.
Massari F, Ciccarese C, Vau N, Santoni M, Montironi R, Cheng L, Marques RC, Scarpelli M, Fonseca J, Matrana MR, Holger M, Cascinu S, Tortora G, Lopez-Beltran A. Massari F, et al. Among authors: matrana mr. Curr Drug Targets. 2016;17(7):757-70. doi: 10.2174/1389450117666160201105537. Curr Drug Targets. 2016. PMID: 26844572
Emerging Immunotargets and Immunotherapies in Prostate Cancer.
Montironi R, Santoni M, Sotte V, Cheng L, Lopez-Beltran A, Massari F, Matrana MR, Moch H, Berardi R, Scarpelli M. Montironi R, et al. Among authors: matrana mr. Curr Drug Targets. 2016;17(7):777-82. doi: 10.2174/1389450117666160217123304. Curr Drug Targets. 2016. PMID: 26898309 Review.
73 results